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Figure 1: 
Germline organisation of T-cell Receptor (TcR) genes
Figure 2: 
Schematic illustration of Ig and TcR gene rearrangement
Dr Shahid Pervez, Histopathology
Dr Tariq Moatter, Molecular Pathology
The molecular diagnosis of lymphoproliferative 
disorders is based on the assumption that the cells 
of a malignancy have a clonal origin reflected by 
t he  p resence  o f  c l ona l l y  r ea r ranged  
immunoglobulin (Ig) and T-cell receptor (TcR) 
1genes . 
T-lymphocytes rearrange their TcR genes to 
encode a unique antigen receptor expressed on 
the surface of T cells (Fig 1). TcR is composed of á, 
â, ã and ä chain genes, which rearrange in the 
germline genome to give a functional T-cell 
receptor. Rearrangements involve random 
assembly of different variable (v), sometimes 
diversity (D) and joining (J) gene segments (Fig 2).
In diagnostic pathology it is relatively easy to 
determine clonality of B-lymphoproliferative 
disorders by immunohistochemical techniques for 
instance by using monoclonal antibodies to kappa 
and lambda light chains to look for light chain 
restriction. However in contrast by routine 
immunohistochemistry it is difficult to establish 
clonality (monoclonality) or otherwise of a              
T lymphoproliferative disorder. The whole idea of T- 
cell receptor gene rearrangement is based on the 
assumption that in T-cell Non-Hodgkin's lymphoma 
(T-NHL) all tumor cells are the progeny of a single 
transformed T-cell that is, they are monoclonal. 
Therefore it will be right to believe that all these 
neoplastic T- cells arrange gene in an identical 
fashion and therefore come to the detection levels 
as a single band by PCR (Fig. 3 and 4). In contrast 
a reactive or in other words polyclonal population 
will have a heterogenous population of T-cells 
arranging TcR genes in variable manner and 
therefore appearing as smear on PCR based gel 
2analysis  (Fig. 3 and 4).
TcR genes undergo VDJ or VJ rearrangements in 
the sequential orders of TcRä, TcRã, TcRâ and 
TcRá. All T-cells undergo rearrangement of at least 
Background
T-Cell Receptor Gene Arrangements
some of the TcR genes. Approximately 95 per cent 
of circulating T cells undergo the entire spectrum of 
rearrangements and are á/â positive but a small 
population of ã/ä T-cells does not undergo â/á 
rearrangements. 
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T-Cell Receptor (TcR) Gene Rearrangement 
Studies: A Useful Adjunct for the Diagnosis 
of T-Cell Lymphoproliferative Disorders
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M    1    17     43     47     61     66     67     73     82     85    91    -C    +C
Figure 3: 
Ethidium bromide-stained 2% agarose gel showing 240 
bp -globin product of different T-NHL samples. M represents 
the molecular weight marker along with negative (-C) and 
positive (+C) controls
Molecular analysis of the TcRâ and TcRã genes is 
commonly used to distinguish monoclonal T-cell 
neoplasms from polyclonal reactive process. The 
reason that TcRä gene is not commonly targeted is 
because it is deleted during TcRá gene 
rearrangement. TcRá gene is not targeted because 
it has so many possible rearrangements that 
current probe technology cannot handle the 
diversity. 
Most TcR gene analysis nowadays are PCR-
based. Because of the complexity of TcRâ locus 
PCR for these rearrangements require a large 
number of primers and thus may not be the 
preferred locus for PCR testing in clinical 
diagnostic scenario. Nonetheless commercially 
available standardised Biomed primers for TcRâ 
3appear to work well in practice .
The rearranged TcRã is ideal for PCR amplification 
for two reasons. First because TcRã locus is 
consistently rearranged prior to TcRâ locus. 
Second, nearly all T-cells harbour rearrangements 
involving one of eleven variable segments. Eight of 
these segments are homologous to one another 
and can thus be targeted by a single consensus 
primer. In the event that one of the remaining 
variable segments was used, additional primers 
are employed in a multiplex fashion, along with 
several joining region primers to detect virtually all 
possible TcRã gene rearrangements. Since this is 
a PCR based test directed against genomic DNA, 
TcR PCR can be performed on paraffin embedded 
tissue.
PCR based TcRã analysis using standardised 
biomed primers result in very few false negative 
results provided the sample is representative. 
Excluding a problem with contamination false 
positive results are most common when only few 
lymphoid cells are present in the sample as 
selective amplification of these few cells may result 
in an apparent positive result (pseudoclonality). 
Testing small samples in duplicate will identify 
these potential false positive cases and will result 
in an oligoclonal pattern of amplification ie, 
different sized gene rearrangements on different 
runs. This should not be interpreted as evidence of 
4a monoclonal population .
False Positive and Negative Results
Lineage Infidelity
Clinical Utility
A monoclonal TcR gene rearrangement does not 
always translate into T-cell lineage as many 
precursor B cell lymphoblastic leukemias and 
lymphomas are positive for such rearrangements 
and vice versa. A mature T-cell lymphoma known to 
5show this phenomenon is AILT type T NHL .
T-cell receptor gene rearrangement studies are 
used to distinguish benign from malignant T-
lymphoid proliferations. Benign reactive T 
lymphoid proliferations do not harbour monoclonal 
rearrangements in control to malignant lymphoid 
tumors. However in spite of its incredible power, 
results of clonality assays should be interpreted 
with caution. It is important to recognize that 
clonality is not always synonymous with 
malignancy. Therefore, all results must be 
i n t e r p r e t e d  w i t h  m o r p h o l o g i c a l  a n d  
6immunohistochemical clinical data .
The test can also be utilised for differentiating T and 
B cell lineage of a lymphoid proliferation. A 
complicating factor is lineage infidelity in a minority 
of cases. 
    
Overall, it has been shown that when diagnostic 
uncertainty remains after morphologic and 
immunopheno typ ic  examina t ion ,  gene  
rearrangement studies are helpful in 72 p  of 
the cases. However, if molecular results appear to 
be in violation with morphologic diagnosis, time-
tested morphologic impression or diagnosis should 
prevail over molecular results.
er cent
Test Samples
Positive Control
TcR â tube A, positive clonal control showing 
clonal  (single) peak
Negative Control
             TcR â tube A, negative control
Figure 4: 
Heteroduplex analysis of 6% ethidium bromide-stained 
polyacrylamide gel illustrates rearranged TcR  PCR products 
for T-malignancy cases, followed with genescan of 2 samples 
showing clonal and polyclonal peaks with controls
TcR â, sample showing clonal (single) peak   
4
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TcR â tube A, positive polyclonal clonal control 
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Dr Aysha Habib Khan, Chemical Pathology
The measurement of vitamin D is becoming 
increasingly important in the management of 
patients with various disorders of calcium 
m e ta b o l i s m  a s s o c i a t e d  w i t h  r i c k e t s ,   
osteomalacia,  neonatal  hypocalcaemia, 
pregnancy, nutritional and renal osteodystrophy, 
hypo and hyperparathyroidism as well as 
osteoporosis.
As calciferol from the skin enters the circulation, it 
is metabolised to several forms, the major form 
being 25-hydroxycalciferol (25-OHD) in the liver. 
Only a small amount is metabolised in the kidney to 
other dihydroxy vitamin D metabolites in man. 
Since 25-OH D is the predominant circulating form 
in the normal population, it is the most reliable 
index of vitamin D status.
Factors such as ultraviolet exposure, season, race, 
and dietary intake are all known to effect levels of 
25-OHD in humans. A decrease in vitamin D levels 
with advancing age has been demonstrated in the 
literature. Anticonvulsants have been shown to 
cause a decrease in 25-OHD levels.  A high 
prevalence (30-90 p ) of sub clinical 25-OHD 
deficiency among normal apparently health 
populations has been observed in many countries, 
particularly in winter months. Studies show high 
prevalence of vitamin D deficiency among 
Pakistani immigrants in western countries. Vitamin 
 D deficiency was also reported among pregnant 
 women in Karachi, Pakistan.Our clinical laboratory 
data at AKUH suggests a high prevalence of 
vitamin D deficiency in patient population 
(unpublished data). 
In Aga Khan Clinical Laboratory, 25-OHD test is 
125performed by a radioimmunoassay using I. The 
calibrators are serum based. The assay is FDA 
approved because of overall simplicity and its 
strong correlation with values obtained from HPLC 
analysis. The assay recognizes both plant and 
animal vitamin D with equal affinity as well as a 
number of other circulating vitamin D metabolites 
like 24, 25 dihydroxyvitamin D, 25, 26 dihydroxy 
vitamin D, 25-OHD3-26-23-lactone. However, as 
these metabolites only account for about 6 p  
of the overall circulating concentration of vitamin D 
and its metabolites, their concentration can be 
ignored under this assay format.
er cent
er cent
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Vitamin D Measurement
Dr Naveen Naz Syed, Haematology 
82-year old male presented with history of 
progressive fatigue and shortness of breath on 
exertion since three months. Physical exam 
showed pallor with mild scleral icterus, and 
palpable liver 2 cm below the left costal margin.
Complete blood count revealed Hemoglobin 
2.7g/dl, hematocrit 7.7 p , MCV 129 fl, MCH 
34.8 pg, white blood cell count 2600/cmm and 
platelets 20,000/cmm.
er cent
QUIZ 
A
B
C
Figure A: Identify red blood cell abnormality.
Figure B: Identify white blood cell abnormality.
Figure C: what is your most likely diagnosis 
after reviewing bone marrow aspirate?
Figure 1:
Aggregation of Platelets in Response to Ristocetin
standardise from laboratory to laboratory, but it is 
the most useful in vitro assay for the diagnosis of 
vWD.
The test will be shortly available at Clinical 
Laboratory, Aga Khan University Hospital.
1. Friedman KD, Rodgers GM. Inherited 
coagulation disorders. In: Greer JP, Foerster J, 
Leukens JN, Rodgers GM, Paraskevas F, 
thGlader B. Wintrobe's Clinical Hematology 11  
Ed. USA; Lippincott Williams and Wilkins 2004: 
1619-67
2. Http://www.uptodateonline.com
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Dr Safoorah Khalid, Haematology
The functional property of von Willebrand factor 
(vWf) that promotes platelet aggregation by the 
drug ristocetin is called ristocetin cofactor activity. 
Ristocetin induces an activation of vWf such that it 
then binds platelets via the platelet glycoprotein 
1(GP) 1b receptor . Ristocetin is an antibiotic that 
was taken off the market because it caused 
2thrombocytopenia in individuals with normal vWf.
Ristocetin cofactor activity is adversely affected by 
loss of larger molecular weight vWf multimers. The 
discrepancy between ristocetin cofactor activity 
and vWf antigen that is observed in qualitative 
defects characterised by loss of both the 
intermediate and high molecular weight multimers 
is thought to be on this basis. Ristocetin cofactor 
activity is also generally used to follow a von 
Willebrand's disease (vWD) patient's response to 
1therapeutic interventions.
In practice, a standard curve for the ristocetin 
cofactor test is constructed by adding serial dilutions 
of a standard plasma preparation (the source of 
vWf) to fresh or formalinized washed platelets and 
then adding ristocetin to a final concentration of 
approximately 1.2mg/ml (figure 1). The time to 
platelet aggregation is measured and graphed 
against the concentration of vWf. The standard 
plasma used for the initial curve should be related to 
the WHO standard.  The results are reported as per 
cent of factor activity as determined by the 
intersection of the test sample slope on the best-fit 
line of the standard dilutions (figure 2). 100 p  
activity equals 100 IU/dl or 1 IU/ml. When using 
Chrono-log Cofactor Assay kit, results of less than 
40 p  are considered abnormal and indicative 
of vWD. However, the individual laboratory utilising 
its particular instrument or reagent combination 
should establish a normal range.
Abnormal tests should be repeated for 
confirmation. However, complete diagnosis and 
determination of the variant forms of vWD requires 
other factors such as family history, bleeding time, 
factor VIII Ag and VIII:C activity.
The ristocetin cofactor test has been difficult to 
er cent
er cent
Ristocetin Cofactor Activity
6
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Figure 2:
Measurement of ristocetin cofactor activity of test plasma 
(red Line) against standard plasma (green line)
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Dr Zishan Haider, Dr Ishtiaq A Chishti, Radiology
Benign bile-duct strictures are usually caused by 
bile-duct injury during cholecystectomy. Less 
common causes include sclerosing cholangitis, 
chronic pancreatitis, congenital abnormalities, and 
nonsurgical trauma. Portal hypertension related 
bile duct changes represent another group of 
uncommon causes of benign stricture, which can 
result in biliary obstruction, choledocholithiasis, 
and cholangitis.
Portal biliopathy is a rare condition that is usually 
not diagnosed. It is associated with presence of 
varix around the bile duct with concomitant 
ischemic damage and structural alterations of bile 
duct wall. This produces obstructive phenomena 
(Fig 1). There are scarce reports in the literature 
about this entity.
In patients with portal hypertension, particularly 
with extrahepatic portal vein obstruction, portal 
biliopathy producing biliary ductal and gallbladder 
wall abnormalities are common. Portal cavernoma 
formation, choledochal varices and ischemic injury 
of the bile duct have been implicated as causes of 
these morphological alterations. While a majority 
of the patients are asymptomatic, some present 
with a raised alkaline phosphatase level, 
abdominal pain, fever and cholangit is. 
Choledochol i thiasis may develop as a 
complication and manifest as obstructive jaundice 
with or without cholangitis. The knowledge of portal 
biliopathy is very important because it is a less 
commonly seen entity in radiology, so accurate 
recognition can make prompt diagnosis.
1. Sumathi B, Randhir J, Sekhar KS, Malathi S, 
Reddy DN, Jayanthi V. Portal biliopathy. J 
Assoc Physicians India - 2006; 54: 483-4.
2. Chandra R, Kapoor D, Tharakan A, Chaudhary 
A, Sarin SK. Portal biliopathy.J Gastroenterol 
Hepatol 2001;16:1086-1092.
3. Nagi B, Kochhar R, Bhasin D, Singh K. 
Cholangiopathy in extrahepatic portal venous 
References
Portal Biliopathy- An Uncommon Cause of 
Biliary Obstruction
obstruction. Radiological appearances. Acta 
Radiol 2000;41:612-615.
4. Khuroo MS, Yattoo GN, Zargar SA, Javid G, 
Dar MY, Khan BA, Boda MI. Biliary 
abnormalities associated with extrahepatic 
portal venous obstruction. Hepatology 1993; 
17:807-813.
(A) Axial post contrast CT scan of abdomen showing moderate 
intrahepatic biliary dilatation without any focal lesion in the liver
(B) Same patient in lower section of abdominal CT 
showing distal common bile duct is encased by 
varices leading to its narrowing and obstruction suggestive 
of portal biliopathy
A
B
Fig 1:  
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Dr Aqsa Nasir, Dr Tariq Moatter, 
Molecular Pathology
Chronic Hepatitis C (HCV) Virus infection is a 
leading cause of cirrhosis, hepatocellular 
carcinoma, gastrointestinal tract haemorrhage and 
hepatic insufficiency. Evolution of latest antiviral 
therapies has reduced the risk of disease 
progression but unfortunately, deaths due to HCV 
are increasing due to inadequate and therefore late 
detection and treatment. However, major 
breakthroughs have been achieved in its diagnosis 
and treatment. Timely diagnosis and an effective 
treatment plan is very important to reduce the high 
mortality rate among patients with HCV infection. 
Several diagnostic tests are available in this 
regard. They are grouped into:     
                                                                                                
! Serological Assay for Antibodies; 
! Molecular Tests for Viral Particles.
Diagnosis of the infection is based on detection for 
serum antibodies against HCV. The virus has an 
incubation period of 2-26 weeks (average 6-7 
weeks). Seroconversion occurs at an average of 2-
3 months. 
Enzymes immunoassays are very sensitive and 
very specific and detect antibodies within 4-10 
week of infection. Immunosuppressed patients can 
have false negative results, including those with 
HIV  infection, renal failure, and HCV  associated 
essential mixed cryoglobulinaemia. Antibodies 
against HCV are still detectable during and after 
treatment, irrespective of therapeutic response.
Once seroconversion occurs, these tests usually 
remain positive. However, the concentration of 
HCV antibodies decreases gradually over time in 
few patients in whom infection spontaneously 
resolves. 
Qualitative HCV RNA tests are based on PCR 
techniques and can detect viral copies as low as 
100 copies of HCV RNA per ml of serum (50 IU per 
ml). This is the most specific test of infection. It is 
Serological Assays for Antibodies
Molecular Tests for Viral Particles
Qualitative PCR Tests 
Laboratory Diagnosis of Hepatitis C:
Transition from Serological to 
Molecular Methods
espec ia l l y  use fu l  when  t ransaminase  
concentrations are normal, when other causes of 
liver disease are present (alcohol consumption), in 
immunosuppressed patients (graft recipients, HIV 
co-infected patients), and in acute hepatitis C 
before antibodies have developed. 
While a single qualitative positive test for HCV RNA 
confirms active viral replication, a single negative 
assay does not exclude viremia and may reflect 
only a viral load below the detection limit of the 
assay. Therefore, a follow-up qualitative HCV RNA 
is required to exclude active HCV replication. Once 
HCV infection is confirmed repeating the test does 
not help in managing untreated patients, except for 
determining whether an acute infection has 
resolved. 
It gives the exact quantity of HCV RNA in the given 
sample. The HCV RNA level can be quantified by 
means of:
Target Amplification Technique (PCR)
Signal Amplification Technique (Branched DNA 
Assay)
Quantification of HCV RNA has no prognostic 
value in predicting the severity of HCV-induced 
liver injury. Viral load is an independent predictor of 
treatment response when assessed before 
therapy, and measurement of viral load is useful in 
monitoring the efficacy of the treatment. In most 
studies, high base line viral load has been defined 
6as greater than 2x10  HCV RNA copies / ml, but 
there is variation in the results of the HCV RNA 
quantification used by the different assays. The 
role of HCV RNA quantification affects the 
treatment plan in the following two ways:
Baseline HCV RNA viral load
The genotype of the HCV 
Patients with high baseline viral loads are less 
likely to achieve a sustained viral response (SVR) 
than those with low viral loads. For example, 7-13 
p  of highly viremic patients in two large trials 
achieved SVR after receiving standard interferon 
therapy alone for 48 weeks, compared with 29-31 
p  with low baseline viral loads.  Patients with 
high viral loads responded well (36-40 p ) 
when treated with combination treatment 
(interferon plus ribavirin) for 48 weeks as 
compared to 24 weeks regimen (27-28 p ). 
However, the results were same in patients with 
HCV Quantification
!
!
!
!
er cent
er cent
 er cent
er cent
low HCV RNA levels at baseline who were treated 
for 24 weeks as compared to those who got the 
therapy for 48 weeks. Regarding treatment with 
peg interferon alpha 2a, patients with pretreatment 
6low viral load (a baseline HCV RNA level of < 2x10  
copies per ml) responded well and were most likely 
to be associated with a SVR than those with high 
viral load. 
The role of the measurement of HCV RNA levels 
for therapy differs in various genotypes. Baseline 
viral load is not necessary in patients with genotype 
2 or 3. However, in monitoring of patients in 
genotype 1 measurement of HCV RNA before 
treatment and again after 12 weeks of treatment is 
very useful and, according to the present 
knowledge, also for those with genotype 4, 5 and 6. 
A 2-log drop at least or undetectable HCV RNA at 
week12 is defined as early virological response 
(EVR) which is now believed to have a poor 
positive predictive value but an excellent negative 
predictive value to SVR. These results will help in 
deciding whether to stop or continue the treatment 
as early as 12 weeks after the start of therapy. 
However, the clinical reliability of serial HCV viral 
load testing in the same patient depends on the use 
of the similar quantitative assay each time.  
Therefore, treatment could be stopped in patients 
with low SVR after 12 weeks of therapy if there is no 
extensive fibrosis. By contrast with HIV infection 
the viral load does not correlate with the severity of 
hepatitis on progression of fibrosis
The advent of serotyping systems has made study 
of the clinical significance of the different types of 
HCV possible. There are six serotypes of HCV, 1, 
2, 3, 4, 5 and 6.
Serological methods are used for the detection of 
antibodies directed to genotype specific HCV 
epitopes. The assay identifies only the types but 
not the sub types of HCV. The concordance with 
molecular assays is around 95 p  and is 
higher for genotype1 than for the others. Mixed 
serologic reactivity is sometimes observed. This 
test cannot distinguish between true mixed 
infection and cross  reactivity or recovery from one 
genotype infection and persistence of viremia with 
another.
On the basis of variations in the nucleotide 
sequence of HCV, six genotypes (numbered 1 to 6) 
HCV Serotyping
HCV Genotyping
er cent
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and more than 100 subtypes (identified by lower 
case letters, for example, 1a and 1b) have been 
identified. The HCV genotype and subtype are 
intrinsic characteristics and do not change during 
the course of the infection. The clinical course, 
including long-term complications of chronic HCV, 
is genotype independent. There is a consensus on 
the fact that the HCV genotypes are predictors to 
the antiviral therapy response. HCV has the 
following genotypes/subtypes identified by reverse 
transcription methods:
1a-1c
2a-2d
3a-3f
4a-4k
5a
6a, 
new subtypes are continuously being discovered. 
Chronic HCV has historically been a difficult to treat 
disease. The primary goal of treatment for HCV is 
eradication of HCV. Clinically this is defined as 
SVR and is evidenced by undetectable HCV RNA 
in serum on sensitive molecular tests performed 24 
weeks after completion of treatment. SVR rates 
have improved over the past decade as new 
treatment strategies have revolutionised the 
treatment plan but despite these improvements in 
overall SVR rates, less satisfactory results have 
been observed in certain patient populations. One 
of the most important related factors is HCV 
genotypes 1 or 4 and a high HCV RNA level before 
treatment.
1. Gianna Dal Molin, Claudio Tiribelli, Cesare 
Campello. A rational use of  laboratory tests in 
the diagnosis and management of hepatitis C 
virus  infection. Annals of Hepatology 2003; 
2(2):April-june:76-83.
2. Stefan Zeuzem. Heterogeneous virological 
response rates to interferon- based therapy in 
patients with chronic hepatitis C: who responds 
less well ? Ann Intern Med. 2004; 140:370-381.
3. Harrison E, Hernandez J Rosati M, et al. 
Hepatic steatosis in hepatitis C   virus genotype 
3 infection: does it correlate with body mass 
index,fibrosis,   and HCV risk factors? Dig Dis 
Sci. 2004 Jan; 49(1): 25-9.
4. Caruntu FA, Benea L. Acute hepatitis C virus 
infection: diagnosis,pathogenesis , treatment. 
J Gastrointestin Liver Dis. 2006 Sep; 15 
(3):249-56.
Clinical Significance of HCV Genotyping
References
Other Laboratory Values on Admission 
Included the Following:
Patient Value Normal Range (Male)
 Reticulocytes 9.2% 0.8-2.0
 LDH 6338 IU/L <170
 T. Bilirubin 8.8 mg/dL 0.3-1.5
 D. Bilirubin <0.1
 B12 <150 pg/mL 211-911
 RBC Folate 805 ng/mL 293-809
 Intrinsic factor Positive Negative 
 Antibody
Dr Naveen Naz Syed, Haematology
The patient is a 82 year old male who presented to 
the emergency department with complains of 
progressive fatigue and shortness of breath on 
exertion over a two-to-three month period. He had 
no history of drug intake, infections, bleeding or 
bruising in the past. However, he had recurrent 
episodes of acid peptic ulcer disease. Physical 
exam showed pallor with mild scleral icterus, lungs 
clear to auscultation, regular heart rate with no 
audible murmurs. Abdomen examination revealed, 
palpable liver 2 cm below the left costal margin, and 
spleen was not enlarged.
A number of laboratory investigations were 
requested including complete blood count, bone 
marrow examination, cytogenetics and various 
biochemical tests. The results are as follows:
Patient Value Normal Range (Male)
 Hemoglobin 2.7 g/dL 12.9-16.9
 Hematocrit 7.7% 38.0-48.8
 MCV 129.7 fL 82.6-97.4
 MCH 34.8 pg 27.8-334
9
 WBC 2.6 x 10 /L 3.8-10.6
 POLYMORPHS 68%
 LYMPHOCYTES 19%
9
 PLATELETS 20 x 10 /L 156-369
Patient History
Complete Blood Count
10
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Answer to Quiz 
Laboratory Diagnosis of Pernicious Anaemia
A
Figures A and B: peripheral smear 40 and 100 X objective 
showing hyper segmented neutrophils and macrocytes
B
C
Figure C: Bone marrow aspirate 100 X objective, 
showing megaloblastic erythropoiesis
Cytogenetics
Pernicious Anaemia
Lab Studies
Normal, 46 X, Y.
Based on the above labs, diagnosis of 
megaloblastic anemia secondary to B12 deficiency 
was made. As the patient was sero-positive for 
intrinsic factor antibodies (IFA), pernicious anemia 
was a likely possibility.
Pernicious anaemia is a rare disorder 
characterised by the inability of the body to 
properly utilise vitamin B12 and, results from the 
lack of the gastric protein known as intrinsic factor, 
without which vitamin B12 cannot be absorbed. 
The symptoms of pernicious anaemia may include 
weakness, fatigue, palpitation, and/or progressive 
neuropathy. Recurring episodes of anaemia 
(megaloblastic) and an abnormal yellow coloration 
of the skin (jaundice) are also common. 
Pernicious anaemia is thought to be an 
autoimmune disorder, and certain people may 
have a genetic predisposition to this disorder. The 
disease is associated with human leucocyte 
antigen (HLA) types A2, A3, and B7 and type A 
blood group.
Anti-parietal cell antibodies occur in 90 p  of 
patients with pernicious an emia but in only 5 p
 of healthy adults. Similarly, binding and 
blocking antibodies to IF are found in most patients 
with pernicious anemia. A greater association than 
anticipated exists between pernicious anemia and 
other autoimmune diseases, which include thyroid 
disorders, type diabetes mellitus, ulcerative 
colitis, Addison  disease, infertility, and acquired 
agammaglobulinemia. An association between 
pernicious anaemia and Helicobacter pylori 
infections has been postulated but not clearly 
proven.
Combined system disease: a history of either 
paresthesia in the fingers and toes or difficulty with 
gait and balance should prompt a careful 
neurological examination. Loss of position sense in 
the second toe and loss of vibratory sense for a 
256-Hz but not a 128-Hz tuning fork are the earliest 
signs of postero-lateral column disease. If 
untreated, this can progress to spastic ataxia from 
demyelination of the dorsal and lateral columns of 
the spinal cord.
1. Peripheral Blood: The peripheral blood 
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usually shows a macrocytic anemia with a mild 
leucopenia and thrombocytopenia. The mean 
cell volume (MCV) and mean cell hemoglobin 
(MCH) are increased, with a mean corpuscular 
hemoglobin concentration (MCHC) within the 
reference range. The leucopenia and 
thrombocytopenia usually parallel the severity 
of the anaemia. The peripheral smear shows 
ova l  macrocytes,  hyper  segmented 
granulocytes, and aniso-poikilocytosis. In 
severe anaemia, red blood cell inclusions may 
include Howell-Jolly bodies, cabot rings, and 
punctate basophilia. The macrocytosis can be 
obscured by the coexistence of iron deficiency, 
thalassemia minor or inflammatory disease.
2. Serum B12 Levels: low.
3. A Bone Marrow Aspirate and Biopsy:
Hype rce l l u l a r  and  show  t r i l i neage  
differentiation.
Erythroid precursors are large and often oval; 
nucleus is large and contains course mottled 
chromatin clumps, providing a checkerboard 
appearance. Nucleoli are visible in the more 
immature erythroid precursors. An imbalance 
in the rate of maturation of the nucleus relative 
to the cytoplasm exists, such that disassociation 
between the maturity of the nucleus and the 
hemoglobinization of the orthochromic 
megaloblastic normoblasts occurs.
Giant metamyelocytes and bands are present, 
and the mature neutrophils and eosinophils are 
hyper segmented.
Imbalanced growth of megakaryocytes is 
evidenced by hyperdiploidy of the nucleus and 
the presence of giant platelets in the smear.
Lymphocytes and plasma cells are spared from 
the cellular gigantism and cytoplasmic 
asynchrony observed in other cell lineages.
4. Intrinsic Factor Antibody: Enzyme linked 
immunosorbent assay (ELISA) is utilised for 
qualitative and semi-quantitative detection of 
antibodies to intrinsic factor in patient serum.
Treatment in our patient included a blood 
transfusion due to the severity of his anaemia, then 
therapy with intravenous cyanocobalamin 
supplements, resulting in stabilization of his 
laboratory values. An important aspect of 
treatment for pernicious anaemia is that it will need 
to be continued lifelong.
Treatment:
Drs Afia Zafar, Erum Khan, Microbiology
Dengue is a mosquito-borne disease that is 
caused by Dengue virus which is usually endemic 
in tropics. Dengue virus family consists of four 
related species (DEN1-DEN4). Infection by one 
type confers immunity to that particular type only, 
but does not protect against other types. In fact; 
second infection by another serotype is more 
serious. 
Dengue virus infection may be asymptomatic or 
may lead to dengue fever (DF) or dengue 
hemorrhagic fever (DHF) or dengue shock 
syndrome (DSS).
The clinical features of DF frequently depend on 
the age of the patient. Infants and young children 
may have a nonspecific febrile disease, often with 
a maculopapular rash. Older children and adults 
may have either a mild flu like illness or the classic 
incapacitating disease with high fever of abrupt 
onset, sometime with two peaks, severe 
headache, pain behind the eyes, muscle and bone 
or joint pains, nausea, vomiting and rash. 
Leucopenia (low white blood cells) and 
thrombocytopenia (low platelets) are frequently 
associated with it. DF is a self limiting disease and 
recovery may be associated with prolonged fatigue 
and depression, especially in adults.
Typical cases of DHF are characterised by four 
major clinical manifestations: high fever, 
haemorrhagic manifestations, enlarged liver and 
circulatory failure.
The condition of patients who progress to shock 
suddenly deteriorates after a fever of 2-7 days 
duration. This deterioration occurs at the time of, or 
shortly after a fall in temperature between the third 
and the seventh day of the disease. There are 
typical signs of circulatory failure: the skin 
becomes cool, blotchy and congested, the pulse 
becomes rapid and patient enters into  a critical 
stage of shock.  
Clinical Feature
Dengue Fever
Dengue Haemorrhagic Fever
Dengue Shock Syndrome
Transmission
Diagnosis
Treatment
Prevention
Personal Protection from Mosquito Bite
Measures to Prevent Mosquito Breeding
These viral illnesses are mosquito borne and by 
and large its transmission is dependent upon 
mosquito bite. The occurrence of DF outbreaks is 
linked to a number of factors such as   density of 
vector (Aedes aegypti), source (an infected febrile 
person) and presence of susceptible hosts in the 
community. The Aedes aegypti mosquito is 
commonly found in urban dwellings, indoors and 
outdoors. Therefore it is easy to speculate that fast 
urbanisation and dense population facilitates the 
progress of outbreak.
Since clinical features are indistinguishable from 
other common diseases, laboratory confirmation of 
dengue virus is important from management and 
epidemiological point of view. Detection of 
antibodies against dengue virus in the blood of the 
infected patient is the simplest method of 
diagnosis. This test is available at the Aga Khan 
University laboratory. However, in some patients 
(30 p ) antibodies may not be detectable 
during the acute phase of the disease in such 
cases special test like PCR is required to confirm 
the diagnosis.
There is no specific anti-viral drug available for the 
treatment of patients with dengue fever. Early 
diagnosis and symptomatic care is the mainstay in 
the treatment. It is important that patients are kept 
well-hydrated. Mild cases managed at home are 
encouraged to take excess fluid and bed rest. 
Severe cases admitted to hospitals are managed 
by intravenous drips and blood /platelet transfusion 
if required.
Use of mosquito repellent and protective clothing is 
an important measure to prevent the viral 
transmission from mosquito bite. Windows and 
doors should be lined with the thin nets to prevent 
entry of mosquitos in the house. Frequent 
insecticide use inside the house is encouraged  
Since there is currently no vaccine available; 
prevention is mainly targeted in the eradication of 
er cent
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Dengue Fever
mosquito breeding points in the community. 
Prevention is only possible if collective effort is 
made by all members of the community. Proper 
disposal of household waste is first and foremost. 
Water in the containers should be stored properly 
with covering lids. Water in flower vases and fridge 
drains should be changed frequently, at least on 
weekly basis. 
Dengue hemorrhagic fever: diagnosis, treatment, 
ndprevention and control. 2  edition. WHO. Geneva.
Dr Riffat Hussain, Radiology
Osteoporosis has been called the “silent disease” 
since damage occurs over many years without any 
evident symptoms until a fracture occurs. A broken 
bone, for some women, may be the first warning 
sign that osteoporosis has occurred.  
Among the available modalities for the diagnosis of 
a low bone mass or osteoporosis bone density 
scanning, also called dual-energy x-ray 
absorptiometry (DXA or DEXA) or bone 
densitometry, is today's established gold standard 
for measuring bone mineral density (BMD).  It is an 
enhanced form of x-ray technology that is used to 
measure bone loss. It is generally performed on the 
lower spine and hips.   DEXA bone density testing 
is the most accurate method available for the 
diagnosis of osteoporosis and is also considered 
an accurate estimator of fracture risk   Bone 
mineral density tests help in diagnosing 
osteoporosis and are more sensitive than ordinary 
x-rays by virtue of detecting bone loss at an earlier 
stage.
The advantages that this technique has to offer are 
that:
! It uses minimal amounts of radiation;
! I t  has a h igh degree of  prec is ion 
(reproducibility). In addition, each time a patient 
returns for a follow-up scan, the prior analysis 
can be used to determine if a change has 
occurred;
! It measures both the lumbar spine and femoral 
neck (the precision is around 1 p  for the 
References
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It allows for standardisation of data based on 
age, weight, height, and ethnic background. 
Aga Khan University Hospital acquired its DEXA 
machine (Hologic Discovery) two years back.  
Since its inception, it has proved itself in helping 
establish osteoporosis in individuals as well as 
identifying patients who have a low bone mass and 
are in need of specific treatments to help in the 
control of further deterioration of their bony mineral 
content. 
The examination is done on an outpatient basis. 
The technique involved is simple with no special 
preparations except the withholding of oral intake 
of Calcium supplements for a day.  However if a 
recent barium examination has been done or a 
patient has been injected with a contrast for a CT 
scan or radioisotope scan, a wait of 10 to 14 days is 
advised before undergoing a DEXA test. 
The test involves a central DEXA examination, 
which measures bone density in the hip and spine 
as the patient lies on a padded table. An x-ray 
generator is located below the patient and an 
imaging device, or detector, is positioned above. 
To assess the spine, the patient's legs are 
supported on a padded box to flatten the pelvis and 
lower (lumbar) spine. To assess the hip, the 
patient's foot is placed in a brace that rotates the 
hip inward. In both cases, the detector is slowly 
passed over the area, generating images on a 
computer monitor.
The test is completed in about 10 minutes and the 
results of the test are reported the next day.
Bone density testing is strongly recommended in 
the following: 
! Post-menopausal females; 
! Personal or maternal history of hip fracture or 
smoking;
! Tall (over 5 feet 7 inches) or thin (less than 125 
pounds) post-menopausal females;
! Patients on medications that are known to 
cause bone loss, including corticosteroids such 
as Prednisone, var ious ant i -seizure 
medications such as Dilantin and certain 
barbiturates, or high-dose thyroid replacement 
drugs;
er cent er cent
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Bone Densitometry (DEXA Scanning) 
in the Diagnosis of Osteoporosis
femoral n ck region.)
! Type 1 (formerly called juvenile or insulin-
dependent) diabetics, liver disease, kidney 
disease or a family history of osteoporosis;
! Patients with high bone turnover, which shows 
up in the form of excessive collagen in urine 
samples;
! Hyperthyroidism;
! Previous history of fracture after mild trauma;
! X-ray evidence of vertebral fracture or other 
signs of osteoporosis. 
Bone Mineral Density Scan of lumbar spine showing osteopenia
Bone Mineral Density Scan of Left Hip showing osteopenia
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Ms Naureen Niaz Ali and Dr Jawaid Jabbar, 
Chemical Pathology
Human immunodeficiency virus (HIV) is a 
retrovirus that causes acquired immunodeficiency 
syndrome (AIDS). In AIDS, there is failure of 
immune system so that the patients are prone to 
life-threatening opportunistic infections. 
There are 2 types of HIV; 1 and 2.  Ninety per cent 
of AIDS patients are affected by HIV-1 worldwide, 
The basic viral proteins of HIV-1 are: (as shown 
diagrammatically in fig. 1 and listed in Table 1 ) 
 DENOMINATION GENOME NATURE
 GP 160 ENV Glycoprotein precursor of 
GP 110/120 and GP 41
 GP100/120 ENV Envelope Glycoprotien
 P68 POL Reverse transcriptase
 P55 GAG Precursor of core protein
 P52 POL Reverse transcriptase
 GP41 ENV Transmembrane Glycoprotein
 P40 GAG Precursor of core protein
 P34 POL Endonuclease
 P24/25 GAG Core protein
 P18 GAG Core protein
The initial approach is to screen the suspected 
individuals for the presence of antibodies to both 
Diagnostic Approach
Screening 
Western Blot for HIV 1 Virus
Figure 1
Schematic Representation of the Structure of HIV-1
Table 1
HIV-1 and HIV-2. At Aga Khan University Clinical 
Laboratory a micro particle enzyme immunoassay 
is use to detect antibodies to both HIV-1 and HIV-2.
False positive results may occur due to the 
following:
1- Hyperlipimic samples;
2- Hemolysed or plasma samples;
3- Multiparous women;
4- Recent recipients of influenza vaccine;
5- Recent recipients of Hepatitis B vaccines;
6- Patients with autoimmune disease.
The confirmation for the presence of the virus 
requires testing with western blot technique to 
identify the basic viral proteins.
The test is based on indirect ELISA technique on a 
nitrocellulose strip containing all the HIV-
1constituent proteins and an internal anti-IgG 
control. Firstly, strip is rehydrated and samples are 
incubated on the strip along with controls. If anti-
HIV1 antibodies are present, they bind to the 
identified viral proteins present on the strip. After 
washing, the alkaline phosphates-labeled anti-
human IgG antibodies are incubated. The 
conjugate binds to Anti-HIV1 antibodies captured 
on the solid phase. After washing, the colour 
development solution allows demonstrating the 
enzymatic activity of the complexes bound to 
nitrocellulose. The appearance of specific 
coloured bands allows demonstrating the 
presence of anti- HIV1 antibodies in the sample.
1- Positive:
Presence of 2 ENV protein and or GAG and or 
POL protein.
2- Indeterminate: 
Presence of 1 ENV protein and or GAG and or 
POL, Presence of a GAG and POL and only 
presence of GAG and POL protein.
3- Negative: 
No bands present on the strip.
Indeterminate results may reflect one of the 
following alternatives:
a) -Seroconversion
b) -HIV-2
c) -Cross reactivity due to the retrovirus.
Confirmatory Testing (Western Blot)
Interpretation 
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UK based radiologists, Sheffield University 
collaborate with AKU for radiology meeting
Reported by Ms Nida Husain, Radiology
T h e  t w o - d a y  e i g h t h  
Sheffield International 
Conference on Diagnostic 
Imaging was held at Aga 
K h a n  U n i v e r s i t y  o n  
January 13 and 14, 2007. 
This biennial conference 
was organised by Sheffield 
Diagnostic Imaging, a 
g r o u p  o f  U K - b a s e d  
physicians and Sheffield 
University UK, and was 
hosted by Aga Khan 
University (AKU). 21 invited speakers from the UK, 
one from Netherlands and four from Aga Khan 
University (AKU) made presentations on various 
sub-specialties and findings from latest research. 
The conference's inaugural session was attended 
by radiology professionals, physicians and 
surgeons  from all over Pakistan, and was opened 
by Mr Hamish Daniel, Deputy High Commissioner, 
British High Commission who also inaugurated a 
concurrent 'Scientific Poster Exhibition' and a 
display of radiology-related equipment. 
 
Eighth Sheffield International 
Conference - Diagnostic Imaging
Mr. Hamish Daniel, Deputy 
High Commissioner, UK
Mr. Hamish Daniel and Prof. Sameh Morcos Inaugurating the Scientific Poster
Exhibition with members of the organising committee
understanding of  the 
dynamic field of radiology, 
presently undergoing very 
rapid change with new 
technology transforming 
this specialty into specific 
subspecialties. Available 
facilities in Pakistan are fast 
i n c r e a s i n g  a n d  t h e  
o r g a n i s e r s  s a w  t h e  
necessity of expanding the 
pool of appropriately-
educated radiologists. It is 
important that not only 
radiologists but all health care providers keep 
abreast of latest trends and technologies. 
 
The conference is a step towards initiating 
collaborative research projects and understanding 
at institutional, national and international levels. 
Over 400 participants attended the conference 
from Pakistan and abroad. The conference was 
accredited 11 Category-1 CPD credits by the Royal 
College of Radiologists of the United Kingdom.
As a part of its social responsibility and 
commitment to the advancement of health 
research and continuing education, AKU regularly 
holds seminars, symposiums and events to raise 
awareness about health and education related 
issues which are of national importance and 
interest.
Dr Zafar Sajjad, Associaate 
Professor, Chairman Organising 
Committee, giving his welcome 
address at the inaugural session 
D r  N a d e e m  A h m e d ,  
Chairman Department of 
R a d i o l o g y ,  A K U H  
welcomed the guests and 
recognised the Sheffield 
Group's contribution to 
promote global education 
through such conferences, 
and especially thanked the 
i n v i t e d  i n t e r n a t i o n a l  
speakers and participants. 
Pro fessor  Dr  Sameh 
Morcos, head of Sheffield 
D i a g n o s t i c  I m a g i n g  
provided an overview of the conference. The chief 
guest Mr Hamish Daniel, stressed upon the 
importance of country-to-country linkages in health 
care, as well as highlighting the sheer significance 
of the human factor not withstanding technological 
innovations. 
A unique feature of the Sheffield International 
Conference was that it is held in developing 
countr ies, enabl ing concerned medical  
practitioners and technicians in these countries to 
familiarise themselves with state-of-the-art 
technologies and innovations, and the existing 
knowledge base. 
Presentations made were 
focused  on  common 
diseases in Pakistan with 
emphasis on both basic 
and advanced imaging 
techniques. Topics covered 
during the conference 
included radiology in 
trauma and haemorrhage, 
oncology, women imaging, 
imaging in  d iabetes,  
v a s c u l a r  i m a g i n g ,  
cardiothoracic imaging, 
neuro-radiology, nuclear 
imaging,  etc.
The conference was designed to provide an 
opportunity to radiologists, technicians and other 
members of Pakistan's medical community to 
expand and build upon their knowledge and 
Dr Nadeem Ahmad, Chairman, 
Department of Radiology, 
at the inaugural session
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Prof. Sameh Morcos, Chairman, 
Sheffield Diagnostic Imaging, 
addressing the inaugural session
Mr Nadeem Mustafa Khan, DG and CEO, AKUH, Captain (R) Habib Khan, 
Manager Radiology, Dr Nadeem Ahmad, Chairman Radiology, 
Mr Hamish Daniel, Deputy High Commissioner, UK,
Dr Sameh Morcos, Chairman Sheffield Diagnostic Imaging, and
Dr Zafar Sajjad, Associate Professor, Chair Organising Committee
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